Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study.

We have recently reported brain atrophy in the early stages of primary progressive multiple sclerosis (PPMS), affecting both grey and white matter (GM and WM). However, to date no clinical or radiological predictors of GM and WM atrophy have been identified. The aim was to investigate short-term changes in GM and WM volumes and to assess the predictive value of demographic, clinical and radiological variables in order to gain a better understanding of the pathological substrate underlying these changes. Thirty-one subjects with PPMS within 5 years of symptom onset were studied at baseline and after 1 year. At baseline, patients underwent neurological examination and were scored on the Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Functional Composite. They had 3D inversion-prepared fast spoiled gradient recalled (FSPGR), dual-echo and triple-dose post-contrast T1-weighted spin echo MRI scans. Proton density and enhancing lesion loads were determined. The 3DFSPGR sequence was repeated after 1 year and brain volume changes were calculated using two techniques, SPM99 (statistical parametric mapping) and SIENA (structural image evaluation, using normalization, of atrophy). Stepwise linear regression models were applied to baseline variables to identify independent predictors of atrophy development. Using SPM99, a decrease in brain parenchymal fraction (-1.03%; P < 0.001) and GM fraction (-1.49%; P < 0.001) was observed. The number of enhancing lesions independently predicted decrease in brain parenchymal fraction (P = 0.019) and decrease in WM fraction (P = 0.002). No independent predictors of GM fraction decrease were found. A mean brain volume change of -0.63% (range -4.27% to +1.18%; P = 0.002) was observed using SIENA, which was independently predicted by EDSS (P = 0.004). Global and GM atrophy can be detected over a 1-year period in early PPMS. The former may be predicted by the degree of inflammation, while the latter seems to be independent of it. SIENA and SPM-based methods appear to provide complementary information.

[1]  F. Barkhof,et al.  Cortical lesions in multiple sclerosis. , 1999, Brain : a journal of neurology.

[2]  Stephen M. Smith,et al.  Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.

[3]  A. Thompson,et al.  One year follow up study of primary and transitional progressive multiple sclerosis , 2000, Journal of neurology, neurosurgery, and psychiatry.

[4]  J. Udupa,et al.  The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS , 2000, Neurology.

[5]  A J Thompson,et al.  Brain atrophy in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.

[6]  M Rovaris,et al.  Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. , 2001, Brain : a journal of neurology.

[7]  B. Trapp,et al.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions , 2001, Annals of neurology.

[8]  T. Perneger What's wrong with Bonferroni adjustments , 1998, BMJ.

[9]  David H. Miller,et al.  Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. , 2002, Brain : a journal of neurology.

[10]  J H Simon,et al.  Eight-year follow-up study of brain atrophy in patients with MS , 2002, Neurology.

[11]  B. Trapp,et al.  Subpial Demyelination in the Cerebral Cortex of Multiple Sclerosis Patients , 2003, Journal of neuropathology and experimental neurology.

[12]  Ludwig Kappos,et al.  Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis. , 2003, Archives of neurology.

[13]  A J Thompson,et al.  Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. , 1996, Brain : a journal of neurology.

[14]  C. Pozzilli,et al.  The Relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis , 2004, Journal of Neurology.

[15]  R. Rudick,et al.  Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.

[16]  Stephen M. Rao,et al.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure. , 1999, Brain : a journal of neurology.

[17]  P. M. Matthews,et al.  Evidence of early cortical atrophy in MS , 2003, Neurology.

[18]  A. Kermode,et al.  Serial Gd-DTPA MRI reveals differences between primary and secondary progressive multiple sclerosis , 1989 .

[19]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.

[20]  A J Thompson,et al.  Diagnostic criteria for primary progressive multiple sclerosis: A position paper , 2000, Annals of neurology.

[21]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.

[22]  A. Goldszal,et al.  Estimating cerebral atrophy in multiple sclerosis patients from various MR pulse sequences , 2002, Multiple sclerosis.

[23]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.

[24]  Massimo Filippi,et al.  Disturbed function and plasticity in multiple sclerosis as gleaned from functional magnetic resonance imaging. , 2003, Current opinion in neurology.

[25]  A J Thompson,et al.  Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis , 2003, Multiple sclerosis.

[26]  F. Barkhof,et al.  Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. , 1998, Brain : a journal of neurology.

[27]  David H. Miller,et al.  Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. , 2004, Brain : a journal of neurology.

[28]  G. Comi,et al.  Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[29]  F. Barkhof,et al.  Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. , 2002, Archives of neurology.

[30]  M. A. Horsfield,et al.  Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI sequences , 2003, Journal of the Neurological Sciences.

[31]  Alan J Thompson,et al.  The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM‐based segmentation methodology , 2002, Journal of magnetic resonance imaging : JMRI.

[32]  A J Thompson,et al.  A comparison of the pathology of primary and secondary progressive multiple sclerosis. , 1994, Brain : a journal of neurology.

[33]  Alan J. Thompson,et al.  Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis , 2004, NeuroImage.

[34]  A. Thompson,et al.  Major differences in the dynamics of primary and secondary progressive multiple sclerosis , 1991, Annals of neurology.

[35]  M. Rovaris,et al.  Quantitative brain volumetric analysis from patients with multiple sclerosis: a follow-up study , 1999, Journal of the Neurological Sciences.